Literature DB >> 11734539

Suppression of revertant fibers in mdx mice by expression of a functional dystrophin.

G E Crawford1, Q L Lu, T A Partridge, J S Chamberlain.   

Abstract

Duchenne muscular dystrophy (DMD) is characterized by progressive muscle degeneration that results from the absence of dystrophin. Despite null mutations in the dystrophin gene, many DMD patients display a low percentage of dystrophin-positive fibers. These "revertant fibers" are also present in the dystrophin-deficient mdx mouse and are believed to result from alternative splicing or second mutation events that bypass the mutation and restore an open reading frame. However, it is unclear what role dystrophin and the dystrophic pathology might play in revertant fiber formation and accumulation. We have analyzed the role of dystrophin expression and the dystrophic pathology in this process by monitoring revertant fibers in transgenic mdx mice that express truncated dystrophins. We found that newborn transgenic mice displayed approximately the same number of revertant fibers as newborn mdx mice, indicating that expression of a functional dystrophin does not suppress the initiation of revertant fiber formation. Surprisingly, when the transgene encoded a functional dystrophin, revertant fibers were not detected in adult or old mdx mice. In contrast, adult transgenic mice expressing a non-functional dystrophin accumulated increasing numbers of revertant fibers, similar to mdx mice, suggesting that positive selection is required for the persistence of revertant fibers. Finally, we provide evidence that the loss of revertant dystrophin in transgenic mdx muscle fibers overexpressing a functional dystrophin results from displacement of the revertant protein by the transgene-encoded dystrophin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734539     DOI: 10.1093/hmg/10.24.2745

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  10 in total

1.  Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Authors:  Wenwei Shao; Xiaojing Chen; Richard J Samulski; Matthew L Hirsch; Chengwen Li
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

2.  Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model.

Authors:  Niclas E Bengtsson; Julie M Crudele; Jordan M Klaiman; Christine L Halbert; Stephen D Hauschka; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2022-02-08       Impact factor: 12.910

Review 3.  Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.

Authors:  Akinori Nakamura
Journal:  J Hum Genet       Date:  2017-06-01       Impact factor: 3.172

4.  Subcellular localization of dystrophin isoforms in cardiomyocytes and phenotypic analysis of dystrophin-deficient mice reveal cardiac myopathy is predominantly caused by a deficiency in full-length dystrophin.

Authors:  Nami Masubuchi; Yuichi Shidoh; Shunzo Kondo; Jun Takatoh; Kazunori Hanaoka
Journal:  Exp Anim       Date:  2013

5.  Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy.

Authors:  Oshrat Levi; Olga Genin; Corrado Angelini; Orna Halevy; Mark Pines
Journal:  Oncotarget       Date:  2015-09-15

Review 6.  Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy.

Authors:  Akinori Nakamura
Journal:  J Pers Med       Date:  2019-03-04

7.  Gene Therapy for Duchenne muscular dystrophy.

Authors:  Julian Ramos; Jeffrey S Chamberlain
Journal:  Expert Opin Orphan Drugs       Date:  2015-10-06       Impact factor: 0.694

8.  Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice.

Authors:  Yusuke Echigoya; Joshua Lee; Merryl Rodrigues; Tetsuya Nagata; Jun Tanihata; Ashkan Nozohourmehrabad; Dharminder Panesar; Bailey Miskew; Yoshitsugu Aoki; Toshifumi Yokota
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

9.  Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice.

Authors:  Rachel M Faber; John K Hall; Jeffrey S Chamberlain; Glen B Banks
Journal:  Skelet Muscle       Date:  2014-05-23       Impact factor: 4.912

Review 10.  Revertant Phenomenon in DMD and LGMD2I and Its Therapeutic Implications: A Review of Study Under Mentorship of Terrence Partridge.

Authors:  Qi Long Lu
Journal:  J Neuromuscul Dis       Date:  2021
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.